In the present study, we aimed to determine the effect on GV of switching patients with T2DM from treatment with a combination of insulin degludec and a DPP-4 inhibitor to IDegLira using ambulatory CGM. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.